Research programme: RGD-targeted TRAIL conjugates - Kreatech BiotechnologyAlternative Names: RGD-avidin-TRAIL conjugate; RGD-TRAIL conjugate
Latest Information Update: 16 Jul 2016
At a glance
- Originator KREATECH Biotechnology
- Mechanism of Action TNF related apoptosis inducing ligand stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Netherlands
- 07 Dec 2005 Preclinical trials in Cancer in Netherlands (unspecified route)
- 07 Dec 2005 Data presented at the 17th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2005) have been added to the Cancer pharmacodynamics section